Dan Buettner
National Geographic Fellow | Five-Time NYT Bestselling Author | Founder of Blue Zones | Emmy-Winning Netflix Host | Longevity & Happiness Researcher
2013 Nobel Laureate in Physiology or Medicine | Professor of Cell Biology, UC Berkeley | HHMI Investigator | Pioneer of Vesicle Trafficking
A 2013 Nobel Laureate whose discoveries revealed how cells transport proteins — insights now embedded in medicine, biotech, and disease research. Professor at UC Berkeley and HHMI Investigator, Schekman also leads ASAP, a global Parkinson's research initiative spanning 165 labs. His talks offer senior audiences a rare window into how foundational science creates lasting impact.
Want to book Randy Schekman as a speaker for your event? Please provide the info below and we’ll get in touch within 24h:
Randy Schekman is a 2013 Nobel Laureate in Physiology or Medicine whose discoveries transformed our understanding of how cells organize and execute the transport of proteins — one of the most fundamental processes in biology. A Professor in the Department of Molecular and Cell Biology at the University of California, Berkeley, and a longtime Investigator at the Howard Hughes Medical Institute, Schekman has spent decades mapping the molecular machinery that governs how cells package, move, and secrete proteins with extraordinary precision.
Nobel Prize speaker Randy Schekman shared the 2013 Nobel Prize with James Rothman and Thomas Südhof for their collective work decoding the vesicle trafficking system — the intricate network of membrane-bound sacs that ferry proteins to the right cellular compartments at the right time. Schekman’s contribution was foundational: using baker’s yeast as a model organism, he identified the genes responsible for regulating vesicle transport, demonstrating that mutations in these genes cause traffic jams within the cell with severe biological consequences. His work established a genetic blueprint for the secretory pathway that has since proven conserved across all eukaryotic life, including humans.
His research laid the scientific groundwork for understanding diseases caused by defects in protein transport, and has informed the biotechnology industry’s use of yeast to manufacture clinically vital proteins such as recombinant human insulin. Among his many honors are the Albert Lasker Award for Basic Medical Research, the Gairdner International Award, the Louisa Gross Horwitz Prize of Columbia University, and election to the National Academy of Sciences.
Beyond the laboratory, Schekman has become one of science’s most outspoken advocates for open access publishing. As founder and inaugural Editor-in-Chief of eLife, the high-profile open-access journal backed by the Howard Hughes Medical Institute, the Wellcome Trust, and the Max Planck Society, he championed a model of scientific communication that prioritizes rigor over prestige metrics. He also served as Editor-in-Chief of the Proceedings of the National Academy of Sciences. In 2018, he took on the role of Scientific Director of Aligning Science Across Parkinson’s (ASAP) — a globally coordinated research initiative partnered with The Michael J. Fox Foundation — now spanning 35 teams across 165 laboratories worldwide, focused on uncovering the molecular origins of Parkinson’s disease.
As a speaker, Randy Schekman brings the rare combination of Nobel-level scientific authority and genuine accessibility to audiences spanning healthcare, biopharma, research institutions, and corporate innovation. His talks translate landmark cell biology into broader lessons about curiosity-driven research, the structures that enable scientific breakthroughs, the politics of academic publishing, and the future of disease research. Senior audiences gain not only scientific insight but a compelling model for how patient, rigorous inquiry — seemingly far from clinical relevance — can yield discoveries that reshape medicine and industry alike.
This keynote traces the intellectual journey behind Schekman's Nobel Prize-winning discoveries — from genetic experiments in yeast to uncovering the universal machinery that governs how cells sort, package, and deliver proteins. More than a scientific retrospective, it explores what it takes to pursue curiosity-driven research without knowing where it leads, and why the most fundamental discoveries often generate the most transformative applications — from insulin production to a deeper understanding of neurological disease.
Schekman is one of science's most prominent advocates for open-access publishing, and in this talk he makes the case for why the closed-journal model is holding back innovation. Drawing on his experience founding eLife and leading major scientific publications, he examines the incentive structures that distort research priorities, the role of prestige in science culture, and what a more transparent, accessible scientific ecosystem would look like — with implications for biopharma, academia, and the institutions that fund research.
As Scientific Director of Aligning Science Across Parkinson's (ASAP), Schekman leads one of the most ambitious coordinated science efforts in recent memory — uniting 35 teams across 165 laboratories to decode the molecular origins of Parkinson's. This talk offers an insider's view of how large-scale collaborative science is organized, what researchers have uncovered about alpha-synuclein and neurodegeneration, and what the next frontier of Parkinson's research looks like. It speaks directly to audiences in healthcare, neuroscience, and any organization invested in the future of disease science.
This keynote makes the case for long-term, curiosity-driven science investment. Using his own career as a throughline — from studying baker's yeast to winning the Nobel Prize to leading a global disease research initiative — Schekman illustrates how discoveries made without immediate application can take decades to yield breakthroughs that change medicine, reshape industries, and save lives. A powerful argument for patient, rigorous research in an era that rewards speed.
| Basic Data Protection Information | |
|---|---|
| Data controller | AURUM SPEAKERS BUREAU S.L. |
| Address | Parc Audiovisual de Catalunya 1, Oficina S11, 08225 Terrassa, Spain |
| Purposes | We will use your data to respond to your requests and deliver our services to you. |
| Marketing | We will only send you marketing correspondence if you have given your prior consent, which you can do by ticking the box for that purpose. |
| Lawful basis | We will only process your data if you have given your prior consent, which you can do by ticking the box for that purpose. |
| Recipients | Generally, only our members of staff who have been duly authorised may access the data that you have provided. |
| Your Rights | You have the right to know what information we hold about you, to rectify it and to erase it, as explained in the additional information available on our website. |
| Additional Information | For more information, please see “PRIVACY POLICY” on our website. |